A randomised phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low dose dexamethasone in multiple myeloma with thalidomide plus dexamethasone salvage therapy for non-responders

Trial Profile

A randomised phase III study of CC-5013 plus dexamethasone versus CC-5013 plus low dose dexamethasone in multiple myeloma with thalidomide plus dexamethasone salvage therapy for non-responders

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Dec 2015 Results of post hoc analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Jul 2014 Treatment table changed from expansion phase to salvage therapy, anti coagulants removed and thalidomide added, design changed from open to double blind and official title changed accordingly.
    • 09 May 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2011; according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top